Premium
Treatment of symptomatic patients with essential thrombocythemia: Effectiveness of anagrelide
Author(s) -
Cacciola Rossella R.,
Cipolla Antonio,
Di Francesco Ernesto,
Giustolisi Rosario,
Cacciola Emma
Publication year - 2005
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20399
Subject(s) - anagrelide , essential thrombocythemia , medicine , intensive care medicine , medline , oncology , platelet , political science , law
We prospectively evaluated the effect of anagrelide (ANA) on platelets, PF4, F1+2, PAP, PAI‐1, and TFPI and erythromelalgia in patients with essential thrombocythemia (ET) receiving anti‐aggregants both pre‐ and post‐ANA. At first, we observed a successful reduction of platelets, which was associated with normalization of platelet coagulant and endothelial function and disappearance of erythromelalgia. Secondly, we found a correlation between PF4 and TFPI and between TFPI and thrombosis, suggesting that erythromelalgia may be caused by platelet‐mediated endothelial activation. These data may indicate that ANA may be efficacy in the treatment of symptomatic patients with ET. Am. J. Hematol. 80:81–83, 2005. © 2005 Wiley‐Liss, Inc.